Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib + Lenalidomide + Dexamethasone in NDMM
NCT01217957Phase 2Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Nov 2010
- Primary completion
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ixazomib in multiple myeloma (MM) (5 arms), sponsored by Millennium Pharmaceuticals. Primary endpoints: Adverse Events and Serious Adverse Events up to 336 days, Objective Response Rate up to 787 days and 3 more. Started Nov 2010; status: completed.
02
Drugs
ixazomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01217957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01217957.